FRONTEO Co., Ltd. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereinafter referred to as FRONTEO) is pleased to announce the launch of the drug discovery support AI system "liGALILEO (reading: Ligalileo)” has been expanded from 1500 to 1.As a result, further multifaceted evaluation of target genes and molecules is possible, and information on rare diseases, which have been attracting increasing attention in recent years, has been enriched, making it possible to provide more useful analysis and information for strategy formulation by pharmaceutical companies. becomes.

　liGALILEO uses FRONTEO's in-house developed natural language analysis AI engine to comprehensively, efficiently, and objectively analyze the potential of genes and molecules as drug discovery targets based on a large amount of academic paper information and medical and pharmaceutical data. Solution.Comprehensive evaluation of the scientific relationship (relevance, causality, sensitivity, superiority) between the target gene and the disease, disease area, disease specificity, organ specificity, severe toxicity, etc. By using AI to score and present a wide variety of complex evaluation indicators, such as the scientific evaluation and marketability evaluation that are essential for selecting target genes and molecules, such as the development status of drugs that target molecules, drug discovery targets can be identified. We support the efficiency and speed up of the work of experts in the selection of

　In drug development, only 2/3 to 1/10 of the target genes/molecules that appear promising in the early stages of development actually make it into the market, and the development period is 15 to 1000 years. The problem is that it requires about 9 billion yen in development costs.In particular, even if we reach PoC (Proof of Concept) testing, which takes an average of nine years from the start of development to demonstrate the efficacy of the drug by administering it to humans, the probability of subsequent success is low, around 30%.This is thought to be due to factors such as the selection of target genes and molecules for drug discovery that rely on animal experiments and insufficient patient stratification.In order to improve the probability of success, a completely new approach such as the use of AI is required in the target search stage to narrow down target genes and molecules, which is the most upstream part of the drug discovery process. FRONTEO believes that liGALILEO will help solve this problem. I'm here.

　FRONTEO realizes efficiency and speed-up of the drug discovery process with an AI engine equipped with an innovative algorithm developed in-house, and contributes to improving the probability of success in new drug development and drug repositioning (diversion of existing drugs). I will come.

■ About FRONTEO　URL:https://www.fronteo.com/
FRONTEO uses in-house developed AI engines "KIBIT", "Concept Encoder" and "Looca Cross" that specialize in natural language processing. We are a data analysis company that extracts meaningful and important information from vast amounts of text data to support corporate businesses. Since its founding in August 2003, it has been operating globally in Japan, the United States, South Korea, and Taiwan, with a focus on legal tech businesses such as "e-discovery (electronic discovery)" and "digital forensic investigation" that support international corporate litigation. has been developed.Based on the AI ​​technology cultivated in this business, since 8 we have expanded our business fields to life science, business intelligence, and economic security. We contribute to solving various problems of companies, such as drug discovery support, dementia diagnosis support, and financial/personnel/sales support. June 2014, 2007 Listed on Tokyo Stock Exchange Mothers (currently Tokyo Stock Exchange Growth). In January 6, we acquired the first-class medical device manufacturing and sales license (license number: 26B2021X1), and in September of the same year, we submitted a controlled medical device sales business (report number: 13 Minato Misei device No. 1).Capital 10350 thousand yen (as of March 9, 3).

* FRONTEO, liGALILEO, conceptencoder, KIBIT, and Looca Cross are registered trademarks of FRONTEO in Japan.